PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2.
Daulat AM, Bertucci F, Audebert S, Sergé A, Finetti P, Josselin E, Castellano R, Birnbaum D, Angers S, Borg JP
Pascal Finetti
Bioinformaticien IPC Equipe
Publications
CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
de Nonneville A, Finetti P, Picard M, Monneur A, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D, Mamessier E, Bertucci F
Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients.
Lopresti A, Acquaviva C, Boudin L, Finetti P, Garnier S, Aulas A, Liberatoscioli ML, Cabaud O, Guille A, de Nonneville A, Da Costa Q, Denicolai E, Pakradouni J, Goncalves A, Birnbaum D, Bertucci F, Mamessier E
RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
de Nonneville A, Finetti P, Mamessier E, Bertucci F
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
Bertucci F, Niziers V, de Nonneville A, Finetti P, Mescam L, Mir O, Italiano A, Le Cesne A, Blay JY, Ceccarelli M, Bedognetti D, Birnbaum D, Mamessier E
Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer.
de Nonneville A, Finetti P, Birnbaum D, Mamessier E, Bertucci F
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.
Bertucci F, Boudin L, Finetti P, Van Berckelaer C, Van Dam P, Dirix L, ViensP, Gonçalves A, Ueno NT, Van Laere S, Birnbaum D, Mamessier E
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, BillonE, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L,Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E,Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, MamessierE, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, BirnbaumD, Chaffanet M
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.
Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, Krishnan S, PosadaJM, Ghosh M, Mamessier E, Wong C, Ferraro GB, Batista A, Wang N, Badeaux M,Roberge S, Xu L, Huang P, Shalek AK, Fukumura D, Kim HJ, Jain RK
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.
Goncalves A, Finetti P, Birnbaum D, Bertucci F
EFA6B regulates a stop signal for collective invasion in breast cancer.
Fayad R, Rojas MV, Partisani M, Finetti P, Dib S, Abelanet S, Virolle V, Farina A, Cabaud O, Lopez M, Birnbaum D, Bertucci F, Franco M, Luton F
Alternative lengthening of telomeres is notsynonymous with mutations in ATRX/DAXX.
de Nonneville A, Reddel RR
Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.
Guo Y, Gabola M, Lattanzio R, Paul C, Pinet V, Tang R, Turali H, Bremond J, Longobardi C, Maurizy C, Da Costa Q, Finetti P, Boissière-Michot F, Rivière B, Lemmers C, Garnier S, Bertucci F, Zlobec I, Chebli K, Tazi J, Azar R, Blanchard JM, Sicinski P, Mamessier E, Lemmers B, Hahne M.
Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
Birnbaum DJ, Begg SKS, Finetti P, Vanderburg CR, Neyaz A, Kulkarni AS, Hank T, Tai EC, Deshpande V, Bertucci F, Birmbaum D, Lillemoe KD, Warshaw AL, Mino- Kenudson M, Fernandez-Del Castillo C, Ting DT, Liss AS
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR,Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E,Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, QuaasA, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK,Zhu AX, Duda DG
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.
Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A
The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype.
Bertucci F, Finetti P, Goncalves A, Birnbaum D
PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.
Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F
Tel1(ATM)-mediated interference suppresses clustered meiotic double-strand-break formation
Valerie Garcia*, Stephen Gray, Rachal M Allison, Tim J Cooper, Matthew J Neale* (*co-corresponding)
Tel1(ATM)-mediated interference suppresses clustered meiotic double-strand-break formation
Garcia V, Gray S, Allison RM, Cooper TJ, Neale MJ
Concerted cutting by Spo11 illuminates meiotic DNA break mechanics
Johnson D, Crawford M, Cooper T, Claeys Bouuaert C, Keeney S, Llorente B, Garcia V, Neale MJ
Phage display and selections on purified antigens
Matz J, Chames P
Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.
Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S